Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
NASDAQ:TRDA
Price:
14.05 USD
1.22%
Market Closed
Updated:
May 9, 2024
Entrada Therapeutics Inc
Research & Development
|
Entrada Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Research & Development
-$99.9m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Entrada Therapeutics Inc's Research & Development?
Research & Development
-99.9m
USD
-99.9m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Research & Development amounts to -99.9m USD.
What is Entrada Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-68%
-68%
Over the last year, the Research & Development growth was -50%. The average annual Research & Development growth rates for Entrada Therapeutics Inc have been -68% over the past three years .
You don't have any saved screeners yet
